somatotropin
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Turner Syndrome
Conditions
Turner Syndrome
Trial Timeline
May 1, 2010 → May 1, 2014
NCT ID
NCT01367834About somatotropin
somatotropin is a pre-clinical stage product being developed by Pfizer for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01367834. Target conditions include Turner Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01367834 | Pre-clinical | Completed |
Competing Products
10 competing products in Turner Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| estradiol | Novo Nordisk | Approved | 84 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| Lonapegsomatropin + Somatropin | Ascendis Pharma | Phase 2 | 49 |
| Somatropin (rDNA origin) | Ipsen | Phase 3 | 74 |